| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6121426 | Journal of Clinical Virology | 2013 | 5 Pages |
Abstract
The CAP/CTM CMV test is more sensitive than pp65 antigenemia and the AMPLICOR MONITOR CMV test in HSCT recipients. The lower limit of quantification and co-linearity with the international WHO standard renders the CAP/CTM CMV test suitable for future clinical trials defining viral load thresholds of CMV therapy.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Laura Cardeñoso, Benjamin A. Pinsky, Irmeli Lautenschlager, Shagufta Aslam, Bryan Cobb, Regis A. Vilchez, Hans H. Hirsch,